Susan Greenfield, Founder and CEO of Neuro-Bio Ltd, shared her insights on the challenges of developing Alzheimer’s disease treatments, and the fundamental flaw with approaches to date on the “European Biopharmaceutical Review”. To read the full article,...
On Saturday the 25th of June, Neuro-Bio’s CEO Susan Greenfield, will speak at the opening session of the EAN 2022 congress, the biggest meeting in Neurology! Her talk will be “Where Neuroscience meets neurology: blowing, expanding, and losing the...
During her trip to Australia, Neuro-Bio’s CEO, Susan Greenfield had an interview with Julie Hare, Education editor for the Australian “Financial Review”. In April, Baroness Professor Greenfield published a research paper that proved a drug developed...
On Monday the 30th of May, Neuro-Bio’s operations director, Sara Garcia-Rates, will be presenting at virtual AIMday in Translational Dementia Research, hosted by the University of Oxford. Sara will be talking about Neuro-Bio’s research in a workshop from 10.15...
Neuro-Bio welcomes Anna Ashton as senior postdoc scientist. Anna has over ten years’ experience in research spanning pharmaceutical, biotech and academic labs. She graduated with a PhD in Medical Sciences from the University of Aberdeen, in which she studied the role...
On Wednesday the 25th of May, Neuro-Bio’s, Susan Greenfield, will travel to Australia to meet the company’s shareholders and investors and will be there until the 4th of June. The office and lab will be open as...
During the week beginning on the 9th of May, Neuro-Bio’ CEO and Operations Director, Susan Greenfield and Sara Garcia-Rates, participated at the events organised by the Belgian Economic Mission to the United Kingdom held in London and Oxford. Click the link for...
On Tuesday the 17th of May, Neuro-Bio’s CEO, Baroness Susan Greenfield, had a debate at the House of Lords, in London. The principal topics for the debate will be education, welfare, health and public services, therefore Susan Greenfield will be talking about...
